Relationship of plasma neuropeptide Y with angiographic, electrocardiographic and coronary physiology indices of reperfusion during ST elevation myocardial infarction

被引:49
作者
Cuculi, Florim [1 ]
Herring, Neil [2 ]
De Caterina, Alberto R. [1 ]
Banning, Adrian P. [1 ]
Prendergast, Bernard D. [1 ]
Forfar, John C. [1 ]
Choudhury, Robin P. [2 ]
Channon, Keith M. [2 ]
Kharbanda, Rajesh K. [1 ,2 ]
机构
[1] John Radcliffe Hosp, Oxford Heart Ctr, Oxford OX3 9DU, England
[2] Univ Oxford, John Radcliffe Hosp, Dept Cardiovasc Med, Oxford OX3 9DU, England
关键词
REDUCES ACETYLCHOLINE-RELEASE; NO-REFLOW; MICROVASCULAR OBSTRUCTION; VAGAL BRADYCARDIA; ANGINA-PECTORIS; CARE UNIT; ADMISSION; PATTERNS; GRADE; FLOW;
D O I
10.1136/heartjnl-2012-303443
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives The co-transmitter neuropeptide Y (NPY) is released during high levels of sympathetic stimulation and is a potent vasoconstrictor. We defined the release profile of plasma NPY during acute ST elevation myocardial infarction, and tested the hypothesis that levels correlate with reperfusion measures after treatment with primary percutaneous coronary intervention (PPCI). Design Prospective observational study. Setting University hospital heart centre. Patients 64 patients (62.6 +/- 11.7 years-old, 73% male) presenting throughout the 24-h cycle of clinical activity with ST elevation myocardial infarction. Interventions PPCI. Main outcome measures NPY was measured (ELISA) in peripheral blood taken before and immediately after PPCI and at 6, 24 and 48 h post-PPCI. Reperfusion was assessed by angiographic criteria, ST segment resolution, invasive measurement of coronary flow reserve and the index of microcirculatory resistance. Results Plasma NPY levels were highest before PPCI (17.4 (8.8-42.2) pg/ml, median (IQR)) and dropped significantly post-PPCI (12.4 (6.5-26.7) pg/ml, p<0.0001) and after 6 h (9.0 (2.6-21.5) pg/ml, p=0.008). Patients with admission NPY levels above the median were significantly more hypertensive and tachycardic and were more likely to have diabetes mellitus. Patients with angiographic no-reflow (less than thrombolysis in myocardial infarction 3 flow and myocardial blush grade >2, n=16) or no electrocardiographic ST resolution (<70%, n=30) following PPCI had significantly higher plasma NPY levels. Patients with a coronary flow reserve <1.5 or index of microcirculatory resistance >33 also had significantly higher plasma NPY levels pre-PPCI and post-PPCI. Conclusions Plasma NPY levels correlate with indices of reperfusion and coronary microvascular resistance.
引用
收藏
页码:1198 / 1203
页数:6
相关论文
共 29 条
  • [1] Microvascular Obstruction Underlying Pathophysiology and Clinical Diagnosis
    Bekkers, Sebastiaan C. A. M.
    Yazdani, Saami K.
    Virmani, Renu
    Waltenberger, Johannes
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (16) : 1649 - 1660
  • [2] CLARKE JG, 1987, LANCET, V1, P1057
  • [3] Optimal reperfusion in ST-elevation myocardial infarction - the role of the coronary microcirculation
    Cuculi, Florim
    De Caterina, Alberto R.
    Kharbanda, Rajesh K.
    Banning, Adrian P.
    [J]. SWISS MEDICAL WEEKLY, 2011, 141
  • [4] Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs
    Gibson, CM
    Cannon, CP
    Murphy, SA
    Ryan, KA
    Mesley, R
    Marble, SJ
    McCabe, CH
    Van de Werf, F
    Braunwald, E
    [J]. CIRCULATION, 2000, 101 (02) : 125 - 130
  • [5] TIMI frame count: A quantitative method of assessing coronary artery flow
    Gibson, CM
    Cannon, CP
    Daley, WL
    Dodge, JT
    Alexander, B
    Marble, SJ
    McCabe, CH
    Raymond, L
    Fortin, T
    Poole, WK
    Braunwald, E
    [J]. CIRCULATION, 1996, 93 (05) : 879 - 888
  • [6] PLASMA NEUROPEPTIDE-Y CONCENTRATIONS IN PATIENTS WITH NEURO-ENDOCRINE TUMORS
    GROUZMANN, E
    COMOY, E
    BOHUON, C
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1989, 68 (04) : 808 - 813
  • [7] Postexercise ischemia is associated with increased neuropeptide Y in patients with coronary artery disease
    Gullestad, L
    Jorgensen, B
    Bjuro, T
    Pernow, J
    Lundberg, JM
    Dota, CD
    Hall, C
    Simonsen, S
    Ablad, B
    [J]. CIRCULATION, 2000, 102 (09) : 987 - 993
  • [8] The effect of a neuropeptide YY1 receptor antagonist in patients with angina pectoris
    Gullestad, L
    Bjuro, T
    Aaberge, L
    Apelland, T
    Skårdal, R
    Kjekshus, E
    Nordlander, M
    Ablad, B
    Pernow, J
    [J]. EUROPEAN HEART JOURNAL, 2003, 24 (12) : 1120 - 1127
  • [9] CHANGES IN CARDIAC NEUROPEPTIDE-Y AFTER EXPERIMENTAL MYOCARDIAL-INFARCTION IN RAT
    HAN, C
    WANG, X
    FISCUS, RR
    GU, J
    MCDONALD, JK
    [J]. NEUROSCIENCE LETTERS, 1989, 104 (1-2) : 141 - 146
  • [10] Neuropeptide Y reduces acetylcholine release and vagal bradycardia via a Y2 receptor-mediated, protein kinase C-dependent pathway
    Herring, Neil
    Lokale, Michael N.
    Danson, Edward J.
    Heaton, Daniel A.
    Paterson, David J.
    [J]. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2008, 44 (03) : 477 - 485